Federated Hermes, Inc. Tcr2 Therapeutics Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$1.0 - $1.62 $9,630 - $15,600	-9,630 Reduced 57.63%	7,081 $10,000
Q4 2022 Feb 13, 2023	BUY	$0.83 - $1.44 $1,357 - $2,354	1,635 Added 10.85%	16,711 $16,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $1,982 - $3,997	1,066 Added 7.61%	15,076 $27,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $3,580 - $4,989	-1,697 Reduced 10.8%	14,010 $41,000
Q1 2022 May 13, 2022	BUY	$2.4 - $4.71 $23,563 - $46,242	9,818 Added 166.72%	15,707 $43,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $26,971 - $49,114	5,889 New	5,889 $27,000
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $1.85 Million - $2.79 Million	-112,795 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $1.03 Million - $1.72 Million	50,535 Added 81.17%	112,795 $2.49 Million
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $1.18 Million - $2.02 Million	61,926 Added 18540.72%	62,260 $1.93 Million
Q3 2020 Nov 12, 2020	BUY	$13.1 - $20.69 $4,375 - $6,910	334 New	334 $7,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.